Escaping High Viral Load Exhaustion: CD8 Cells with Altered Tetramer Binding in Chronic Hepatitis B Virus Infection by Reignat, Stephanie et al.
 
1089
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/05/1089/13 $5.00
Volume 195, Number 9, May 6, 2002 1089–1101
http://www.jem.org/cgi/doi/10.1084/jem.20011723
 
Escaping High Viral Load Exhaustion: CD8 Cells with 
Altered Tetramer Binding in Chronic Hepatitis B
Virus Infection
 
Stephanie Reignat,
 
1
 
 George J.M. Webster,
 
2
 
 David Brown,
 
2
 
Graham S. Ogg,
 
3
 
 Abigail King,
 
3 
 
Suranjith L. Seneviratne,
 
3
 
Geoff Dusheiko,
 
2
 
 Roger Williams,
 
1
 
 Mala K. Maini,
 
1
 
and Antonio Bertoletti
 
1
 
1
 
Institute of Hepatology, University College London, London WC1 E6HX, United Kingdom
 
2
 
Centre for Hepatology, Royal Free Campus, Royal Free and University College Medical School, London NW3 2QG, 
United Kingdom
 
3
 
Molecular Immunology Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, 
United Kingdom
 
Abstract
 
Deletion, anergy, and a spectrum of functional impairments can affect virus-specific CD8 cells
in chronic viral infections. Here we characterize a low frequency population of CD8 cells
present in chronic hepatitis B virus (HBV) infection which survive in the face of a high quan-
tity of viral antigen. Although they do not appear to exert immunological pressure in vivo,
these CD8 cells are not classically “tolerant” since they proliferate, lyse, and produce antiviral
cytokines in vitro. They are characterized by altered HLA/peptide tetramer reactivity, which is
not explained by TCR down-regulation or reduced functional avidity and which can be re-
versed with repetitive stimulation. CD8 cells with altered tetramer binding appear to have a
specificity restricted to envelope antigen and not to other HBV antigens, suggesting that mech-
anisms of CD8 cell dysfunction are differentially regulated according to the antigenic form and
presentation of individual viral antigens.
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Introduction
 
During persistent virus infections antigen-specific CD8 T
cells and viral antigens are able to coexist as a possible result
of different mechanisms. Functionally active CD8 cells may
exert selective pressure on the virus leading to the emer-
gence of T cell escape virus mutants (1), or the virus might
possess strategies to avoid recognition by CD8 T cells by
altering the processing or presentation of viral antigen (2).
In other cases the production of viral antigen may lead to
the exhaustion of virus-specific CD8 cells (3, 4) or to the
selection of virus-specific T cells with altered functions (5–
10). These mechanisms are present to variable degrees in
different persistent virus infections and can change in rela-
tion to the dose or strain of infecting virus, genetic back-
ground, and age of the host (11).
 
Hepatitis B virus (HBV)
 
*
 
, a noncytopathic, hepatotropic
DNA virus, is one of the important pathogenic viruses able
to establish a persistent infection in man, which may lead to
the development of cirrhosis and hepatocellular carcinoma.
Approximately 300 million individuals are chronically in-
fected worldwide (12). Mutations in relevant CTL epitopes
(13, 14) or down-regulation of MHC class I molecules (15)
have been demonstrated and are likely to play a role in per-
sistence. However, the main immunological feature that
characterizes chronically infected patients is a state of rela-
tive hyporesponsiveness of HBV-specific T cells compared
with that demonstrable in those patients who control the
virus replication after acute infection (16). Whether this T
cell hyporesponsiveness is caused by deletion of specific
cells (negative selection, exhaustion) or by functional toler-
ance (anergy, cytokine imbalance) has not been fully tested.
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Clonal deletion of HBV-specific T cells as a consequence
of transplacental HBV infection (in vertically infected pa-
tients) and the exhaustion of antiviral CTL by high dose of
antigen (in adult infection) are likely to substantially reduce
the number of HBV-specific T cells in chronically infected
patients (16). Nevertheless, HBV-specific T cells are not
completely deleted. Vaccination with HBsAg of neonatally
infected babies is effective at inducing the clearance of
HBV (17), suggesting that T cells are still present and func-
tionally active. Similarly when adults achieve spontaneous
(18) or drug-induced (19) control of HBV replication,
functionally efficient HBV-specific CD8 cells in the circu-
lation may be demonstrated and expanded. Since these data
suggest that some HBV-specific CD8 cells escape deletion,
whether these cells are functionally active, how they sur-
vive, and what their contribution is to the control of the
virus infection, remain important unresolved questions.
In this study, to evaluate the biological properties of the
HBV-specific CD8 population persisting in chronic hepati-
tis B patients with a high level of replicating virus, we used
in parallel MHC/peptide tetramers and intracellular cyto-
kine staining (ICCS) both directly ex vivo and after in vitro
expansion. The use of more than one technique is neces-
sary since in the presence of antigens, CD8 T cells may ei-
ther lack functional activity or reactivity with the specific
HLA-class I tetramers (11). We present data showing that a
low frequency CD8 cell population is able to escape pe-
ripheral deletion and persist in the face of a high dose of
viral antigen, displaying altered reactivity to the specific
HLA-tetramer. We also explore mechanisms responsible
for the reduced reactivity of these cells with HLA-peptide
tetramers and their functional capacity in vitro. In addition
we show that CTLs with these characteristics have reactiv-
ity restricted to the envelope antigen, suggesting that, as
seen in mice (9), strategies of CD8 impairment may be dif-
ferentially regulated according to the dose and presentation
of individual viral antigens.
 
Materials and Methods
 
Patients.
 
10 HLA-A2 positive adult subjects were studied.
Three had an acute self-limited HBV infection at least 1 y before
this study (referred to as “immune patients”), and seven patients
were chronically infected, with HBV-DNA 10
 
5
 
–10
 
9
 
 copies per
milliliter and with elevated alanine transaminase values (normal
range 
 
 
 
40 IU/L) for 
 
 
 
6 mo before the study. All patients were
negative for antibodies to hepatitis C virus (HCV), delta virus,
and to HIV-1,2. Sequencing of the core and envelope HBV ge-
nome of the immune patients at the time of acute infection
showed that the core 18–27, envelope 183–91, and envelope
348–57 sequences corresponded with the index peptides used for
HLA-tetramers and peptide stimulation.
 
Virological Assessment.
 
HBsAg, anti-HBs, total and IgM anti-
HBc, HBeAg, anti-HBe, anti-delta, anti-HCV, anti HIV-1, and
anti–HIV-2 were determined by commercial enzyme immunoas-
say kits (Abbott Laboratories, Ortho Diagnostic System, and
Sanofi Diagnostic Pasteur). HBV-DNA level was quantified by
using the Roche Amplicor Monitor assay (Roche Laboratories),
with a DNA detection limit threshold of 400 copies per milliliter
 
(0.0014 pg/ml). HBsAg in patients’ serum was quantified using
the Murex HBsAg Version 3 kit (Abbott Murex). The manufac-
turer’s instructions were followed throughout with the inclusion
of a standard curve made from dilutions of the 2nd British Work-
ing Standard for HBsAg (NIBSC). Serial dilutions of patients’ sera
were tested (usually 10
 
 
 
4
 
–10
 
 
 
6
 
) to ensure results within the range
of the assay. All dilutions were made in normal human serum.
 
PCR and HBV DNA Sequencing.
 
DNA was extracted from
serum samples taken at the time of liver biopsy using QIAamp
DNA Blood minikit (QIAGEN). The HBV-DNA was amplified
with primers specific for the HBV core and envelope genes, as
described previously (13). The amplicons were purified and core/
envelope regions were sequenced directly using ABI 377 Auto-
mated Sequencer (Applied Biosystems).
 
Antibodies.
 
For flow cytometry we used the following FITC
PE or CyChrome-conjugated antibodies: anti-CD8 (RPA-T8);
CD3 (HIT3a); CD27 (M-T271); CD28 (CD28.2) CD38
(HIT2); CD45RA (HI100); CD45RO (UchL1); CD56 (B159);
CD62L (Dreg-56); HLA-DR (TU-36); 
 
 
 
/
 
 
 
 TCR (T10B9.1A-
31) (BD PharMingen); CCR-3 (61828.111); CCR-5 (45549.11);
CXCR-3 (49801.11); IFN-
 
 
 
 (25723); IL-4 (3007.11) (R&D Sys-
tems); IFN-
 
 
 
 (B27); and IL-10 (Jes3–9D7) (Caltag).
For TCR analysis: (V
 
 
 
1, V
 
 
 
2, V
 
 
 
3, V
 
 
 
5.1, V
 
 
 
5.2, V
 
 
 
6.1,
V
 
 
 
8, BV11, V
 
 
 
12, V
 
 
 
13.1, V
 
 
 
13.6, V
 
 
 
14, V
 
 
 
16, V
 
 
 
17, V
 
 
 
20,
V
 
 
 
21.3, V
 
 
 
22; Immunotech) FITC-conjugated antibodies.
 
Synthetic Peptides.
 
Peptides corresponding to the HBV geno-
type D sequence, and single amino acid substituted env 183–91
were purchased from Chiron Mimotopes (Clayton) or from
Primm. Purity of peptides was 
 
 
 
90% by HPLC analysis.
 
Staining with HLA-tetrameric Complexes.
 
HLA-class I tetramers
were produced as described previously (20). Tetramer staining
of directly purified cells or T cell lines were performed normally
at 37
 
 
 
C for 20 min in RPMI 1640 plus 10% FCS. Cells were
then washed, suspended in PBS plus 1% FCS. and mAbs against
CD8 or different surface molecules were added at 4
 
 
 
C for 30
min. After further washings, cells were analyzed on FACSort™
(Becton Dickinson) using CELLQuest™ software immediately or
after addition of 1% paraformaldehyde.
 
Intracellular IFN-
 
 
 
 Staining.
 
Ex vivo purified PBMCs or
short-term T cell lines were stimulated at 2–3 
 
 
 
 10
 
6
 
 cells per mil-
liliter in RPMI 1640, 10% FCS with or without peptides, or with
different APC pulsed with peptides for 6 h at 37
 
 
 
C in the pres-
ence of Brefeldin A (Sigma-Aldrich) at 10 
 
 
 
g/ml. Cells were
washed, stained with Cy-chrome conjugated anti-CD8 antibodies
(or different surface markers in selected experiments), then per-
meabilized and fixed using Permeafix (Ortho Diagnostic Systems)
according to the manufacturer’s instructions. FITC-conjugated
anticytokine antibodies or isotyped-matched control were added
(20 min, 4
 
 
 
C), washed twice and analyzed by flow cytometry. In
inhibition experiments, T cell lines were incubated with HLA-A2
plus EBV-B cells or macrophages previously incubated with syn-
thetic peptides in the presence of different concentrations of puri-
fied anti-CD8 antibody (clone RPA-T8; BD PharMingen) or
with anti-IgG
 
1
 
 isotype control (MOPC-21; BD PharMingen).
Experiments were then performed as indicated above.
 
Proliferation Assay using CSFE.
 
For cell proliferation assays,
cells were labeled with CFSE (Molecular Probe) as described pre-
viously (21). Briefly, PBMCs were incubated with 1 
 
 
 
M CSFE
in PBS at 37
 
 
 
C for 9 min, before stimulating with peptides. Cells
were examined the same day of CSFE staining or after 8–9 and
12 d of in vitro culture for evidence of loss of CSFE intensity.
 
Lytic Assays.
 
Cytotoxic activity was assessed by incubating
the T cell lines with Cr
 
51
 
-labeled HLA-A2 matched target cells 
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(EBV-B cells or macrophages) for 4–5 h in round-bottomed
plates. Target cells were either incubated with synthetic peptides
or infected with a recombinant Modified Vaccinia Ankara
(Oxxon Pharmaccines, Ltd.) carrying HBsAg or a Melanoma tu-
mor epitope as control. Infection and expression of antigen was
performed as described previously (22).
 
Production of T Cell Lines.
 
PBMCs were suspended at a con-
centration 2–3 
 
 
 
 10
 
6
 
 cells per milliliter in complete T cell me-
dium (MEM 
 
 
 
 medium [GIBCO BRL], supplemented with 25
mM Hepes, 2 mM 
 
L
 
-glutamine, 0.5 mM nonessential AA, and
10% FCS). Cells were stimulated with synthetic peptides in a 96-
well plate. Recombinant IL-2 (20 IU/ml) was added on day 4–5
of culture and cells were analyzed after a total of 10–12 d of cul-
ture (referred to as short term lines). Oligoclonal lines and clones
were further purified by selection of IFN-
 
 
 
–producing cells using
MACS
 
® 
 
Secretion Assay (Miltenyi Biotec) or separating CD8
 
 
 
cells with microbeads (Dynal AS). Selected cells were then seeded
in 96-well plates, at concentrations of 1–10–50 cells per well with
allogenic irradiated PBMCs (1–2 
 
 
 
 10
 
5
 
 cells per milliliter) in
complete T cell medium plus 20 U/ml IL-2 and 10 ng/ml IL-7
(R&D Systems). Wells were restimulated with irradiated feeder
cells approximately every 2 wk. Growing cells were tested for
peptide specificity with ICCS.
 
Results
 
Identification of Tet/Neg Cells in Chronic HBV Patients.
 
The quantity and function of HBV-specific CD8 cells were
analyzed in three HLA-A2
 
 
 
 subjects who had recovered
from symptomatic acute HBV infection, and in six HLA-
A2
 
 
 
 subjects with chronic hepatitis B (3 HBeAg
 
 
 
, HBV-
DNA 10
 
7
 
–10
 
9
 
 copies per milliliter; 3 HBeAg negative,
HBV-DNA 10
 
5
 
–10
 
7
 
 copies per milliliter). The study was
focused on the following four well-described HLA-A2–
restricted HBV-CTL epitopes: core 18–27; envelope 183–91;
envelope 348–57; and polymerase 816–24. The frequency
of these HBV-specific CD8 cells was quantified by HLA-
tetramers or by ICCS, either directly ex vivo or after 10 d
of in vitro expansion. Cells were stimulated once with 1
 
 
 
M of peptide, a concentration that was unable either to
stimulate directly or to expand in vitro HBV-specific CD8
cells in uninfected individuals (data not shown). We found
that subjects who had recovered from symptomatic acute
hepatitis B (hereafter referred to as “immune”) had HBV-
specific frequencies of around 0.2–0.5% of total CD8.
Analysis using ICCS and tetramers gave a similar pattern of
response but HLA-tetramers were often able to detect more
HBV-specific CD8 cells than ICCS (see for example, Fig. 1
patient 1). Cells specific for all the four epitopes expanded
efficiently in vitro and produced IFN-
 
 
 
 (and not IL-4 or
IL-10, data not shown). The frequency, hierarchy, and
function of these HBV-specific CD8 responses were stable
in repetitive assays performed over a follow up of 
 
 
 
2 y. We
were never able to detect the presence of peptide-induced
IFN-
 
 
 
 positive CD8 cells in the absence of the specific tet-
ramer positive (tet/pos) CD8 cells in this group of patients.
The pattern of CD8 response in chronically infected pa-
tients was different. As already reported (20), direct ex vivo
analysis of circulating HBV-specific CD8 cells using HLA-
 
tetramers were around the background level (0.03%) calcu-
lated in control subjects (HLA-A2 plus nonHBV–infected
and HLA-A2-HBV–infected subjects). However, direct
ICCS assays using 1 
 
 
 
M envelope peptides were able to vi-
sualize a population of IFN-
 
 
 
 (and not IL-4– or IL-10–)
producing CD8 cells in the absence of specific tetramer
binding in 4 out of 6 patients. Although direct ex vivo fre-
quency was low in most of the chronic patients (see pa-
tients 4–6, frequency of 
 
 
 
0.04% above the nonstimulated
value), in some patients (see patient 7) the env 183–91 pep-
tide elicited IFN production by 0.11% of circulating CD8
cells. This frequency is comparable to the direct frequency
of the HBV-specific CD8 cells in immune patients (Fig. 1
patients 1–3).
ICCS and tetramer staining of CD8 cells performed after
peptide stimulation and 10 d of in vitro expansion con-
firmed the discrepancy between the two methods found di-
rectly ex vivo, with values of IFN-
 
 
 
–producing CD8 cells
as high as 10% (patients 4 and 7) in the absence of tetramer
staining. These data suggest the presence of tetramer nega-
tive (tet/neg) antigen-specific CD8 cells. This population
of cells was confirmed by triple staining performed both di-
rectly ex vivo and after expansion (Fig. 1 panel c).
Circulating tet/neg antigen-specific CD8 cells were only
evident in chronically infected subjects and their specificity
appeared to be restricted to envelope antigens. Whereas
core 18–27 and polymerase 816–24 specific CD8 cells were
visualized by both tetramer and ICCS, the same patient
possessed envelope-specific CD8 cells which did not react
with tetramers (Fig. 2). The absence of circulating tet/pos
envelope-specific cells prompted us to investigate whether
these cells were preferentially sequestrated within the liver.
Analysis of intrahepatic T cells in patients with chronic
hepatitis B undergoing liver biopsy failed to reveal intrahe-
patic compartmentalization of Te183–91 positive CD8
cells (Table I). However, the paucity of T cells obtained
from liver biopsies did not allow a parallel analysis of IFN-
 
 
 
–producing cells, precluding testing whether tet/neg-
envelope specific cells were present in the liver of these pa-
tients. Lack of reactivity of envelope-specific CD8 cells in
chronic patients toward the specific tetramers was con-
firmed using two different preparations, a range of tetramer
concentrations (from 1, 2, and 5 
 
 
 
g/ml) and performing
the staining at 4 and 37
 
 
 
C (data not shown). The inability
of HLA-A2 tetramers to bind to envelope-specific cells is
not due to expression of different HLA-A2 subtypes since
all the chronic patients (4–7) carried the common HLA-
A201 allele subtype. The HLA-restriction of the envelope
peptide recognition was investigated by using HLA-A2
positive and negative target cells. Recognition of only
HLA-A2 positive pulsed target cells excluded the possibil-
ity that the IFN
 
 
 
 tet/neg cells were activated by presenta-
tion of envelope peptides through different HLA-class I
molecules. Envelope epitopes were recognized not only as
synthetic peptides, but also after the processing of endoge-
nously synthesized envelope antigen by a vaccinia virus
(data not shown). 
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Functional T Cell Avidity and TCR Expression of Tet/Neg
CD8 Cells.
 
To investigate the mechanism underlying the
lack of tetramer reactivity, we first examined whether tet/
neg cells represented a population of T cells with lower
TCR functional avidity than the tet/pos cells. Tet/neg (pa-
tient 7, chronic) and tet/pos (patient 1, immune) envelope
183–91-specific CD8 cells were either stimulated directly
with different concentrations of peptide, or using HLA-
A2
 
 
 
 macrophages from an uninfected individual pulsed
with the indicated concentrations of peptides (Fig. 3 a).
Equivalent concentrations of envelope peptide (10 nM/1
nM) were necessary to activate the tet/neg or the tet/pos
envelope specific CD8 cells. Identical results were obtained
when CD8 lines from the other chronic patients were
compared with lines of immune subjects (data not shown).
Then, we evaluated whether reduced TCR or CD8 ex-
pression could explain the inefficient tetramer binding (23).
A tet/neg CD8 line (short term line after 10 d in vitro ex-
pansion) containing a population of envelope-specific CD8
Figure 1. Identification of tet/
neg CD8 cells. (A) Detection of
epitope-specific CD8 cells with
HLA-A2 tetramers and with
ICCS. Dot plots are representa-
tive of results obtained in “im-
mune” and chronic patients.
Numbers indicate the frequency
of double positive cells (tet/
CD8  or IFN- /CD8 ) directly
ex vivo (top dot plots) or after 10 d
in vitro expansion (bottom dot
plots). (B) Frequency of tet/
CD8  and IFN- /CD8  cells in
the indicated group of patients
directly ex vivo or after 10 d ex-
pansion. Frequency of IFN- /
CD8  cells were calculated after
subtraction of double positive
cells obtained in nonstimulated
cells. The background level of
direct ex vivo tetramer staining
(value 0.03% of CD8  cells) has
been calculated in HLA-A2 
noninfected subjects and in
HLA-A2 negative HBV-infected
patients; this is indicated as a dot-
ted line. (C) Visualization of tet/
pos and tet/neg cells producing
IFN-  directly ex vivo and after
10 d in vitro expansion in two
representative patients. Dot
plots represent live CD8 gated
cells. Numbers indicate the rela-
tive frequency of the cells in the
different quadrants.
 
Figure 2.
 
Tet/neg CD8 cells are specific only for envelope epitopes.
Dot plots obtained with tetramer staining and ICCS of CD8 lines specific
for the indicated core, envelope and polymerase epitopes. Lines were se-
lected by stimulating PBMCs of patient 5 (chronic HBV) in vitro with
the corresponding peptides for 10 d. 
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Table I.
 
Patients
HLA-A2
 
+
 
HBeAg
HBV-DNA
10
 
6 
 
cells/ml ALT U/L Tc18-27 Te183-91 Tp575-83
T HIV gag
77-85
Patient 5 Neg 0.8
 
   
 
106 74 1.1% 0.02% ND ND
Patient 7 Pos 210   106 227 0.3% 0.08% 0.1% ND
Patient 8 Pos 40   106 505 0.1% 0.2% 0.3% 0.2%
Patient 9 Pos 20   106 120 0.04% 0.02% 0.2% 0.1%
Patient 10a Pos 15   106 120 0.01% 0.02% 0.01% ND
Background level staining of CD8 cells in biopsies from HLA-A2 negative patients with chronic hepatitis B was 0.1% (data from four patients not
shown).
aPatient 10 had a detectable circulating population of tet/neg env 183-91 specific CD8 cells (5% of total CD8 after 10 d in vitro expansion, data
not shown).
Figure 3. Characterization of tet/neg CD8 cells. (A) Functional TCR avidity of env183 specific CD8 lines: env 183-specific CD8 line of immune
patient 1 (tet/pos) and chronic patient 7 (tet/neg) were expanded in parallel in vitro. 8 d after the second round of in vitro stimulation, IFN-  produc-
tion, and tetramer staining of CD8 cells was examined. Lines were stimulated with peptide alone or with peptide-pulsed irradiated HLA-A2  APC.
(B) TCR expression of tet/neg CD8 cells. A representative short-term line (10 d in vitro expansion) of patient 4 is shown. The line was tested for
Te183–91 staining (left dot plots) and in parallel stained with anti-CD3 and analyzed for IFN-  production after specific peptide stimulation. Dot
plots of ICCS represent gated CD8 cells and show CD3 expression of nonstimulated and peptide-stimulated CD8 cells. Percentage of CD8 TCRlow is
shown in the bottom left quadrant. (C) The expression of CD3 and CD8 molecules by env 183–91 specific CD8 cells of patient 2 (immune) and pa-
tient 5 (chronic) was determined in parallel by gating on IFN-  plus CD8 cells after stimulation with env 183–91 peptide (1  M). At the time of ex-
periments, short term lines were also tested in parallel for tetramer-specific binding and the env 183–91 specific line of patient 5 did not have Te183–91/
CD8  cells. Similar results were obtained with lines of other two chronic patients (patients 4 and 7). (D) Anti-CD8 equally inhibits tet/pos and tet/neg
env-specific CD8 lines. Short-term CD8 lines (10 d in vitro expansion) of chronic patient 7 and immune patient 1 were incubated with the indi-
cated concentrations of anti-CD8 and then stimulated with different doses of peptides. Data are presented as percentage of inhibition calculated by
dividing the numbers of IFN- –producing cells in the presence of anti-CD8 with the numbers observed in the absence of antibody. Original mag-
nification:  100.1094 Tetramer Negative CD8 Cells in Chronic Hepatitis B
cells showed a homogeneous pattern of CD3 staining be-
fore restimulation, with no subpopulation of down-regu-
lated cells visible (Fig. 3 B). Furthermore, the level of CD3
expression of envelope 183–91 specific IFN  tet/neg CD8
cells after peptide-specific stimulation was equivalent to the
level found in IFN  tet/pos cells (Fig. 3 C).
Likewise, in these short-term lines, CD8 molecule ex-
pression levels were not reduced in tet/neg cells, but in-
stead were consistently higher in tet/neg than in tet/pos
cells (Fig. 3 C). This suggests that the CD8 molecule could
contribute to the overall functional avidity observed in tet/
neg cells. The importance of the CD8 molecule in the acti-
vation of envelope-specific CD8 cells was confirmed by in-
hibition experiments with anti-CD8 antibody, showing a
comparable level of CD8 dependence in both envelope-
specific CD8 populations (Fig. 3 D).
Repetitive In Vitro Stimulation Enhances Tetramer-binding
Ability. Then, we investigated whether repetitive in vitro
stimulation could convert tet/neg cells to a tet/pos pheno-
type. This conversion has been shown in a mouse model of
influenza virus infection and attributed to the ability of in
vitro restimulation to reorganize the display of TCR (21,
24). In agreement with this work, tetramer env 183–91-
positive cells became detectable after repetitive in vitro
stimulation of IFN  tet/neg CD8 cells. 2–3 rounds of in
vitro stimulation were necessary in chronic patients 3–5
(Fig. 4 A), whereas we were unable to convert cells of pa-
tient 7 even after 3 rounds of stimulation (40 d of in vitro
expansion (data not shown).
Although repetitive in vitro stimulation may reorganize
the TCR display to allow HLA-tetramer binding (24, 25),
the “converted” tet/pos envelope-specific CD8 cells retain
unique characteristics. This was evident when tetramer
staining of these cells and of conventional tet/pos CD8
cells was performed at different temperatures. Whereas spe-
cific staining intensity was increased at 37 C in all the clas-
sical tet/pos cells, the numbers (data not shown) and in-
tensity (Fig. 4 B) of converted tet/pos-CD8 was less
temperature dependent.
This confirmed that the envelope-specific CD8 cells of
chronic patients are not classical “low affinity” tetramer-
binding cells, since in this case staining performed at 37 C
should eliminate any binding seen at 4 C (26). At the same
time, the temperature independent binding of converted
tet/pos cells suggests a lack of active participation in the
staining process, since redistribution of the TCR and HLA-
tetramer internalization would be maximal at the physio-
logical temperature (26). In line with this interpretation,
converted tet/pos cells also had an altered pattern of decay
(Fig. 4 C). Envelope-specific CD8 cells of chronic and im-
mune patients were stained with tetramers and after wash-
ing the tetramer-dissociation rate was analyzed. The inten-
sity of tetramer-binding in envelope-specific CD8 cells
from chronic patients had a more pronounced decay com-
pared with envelope-specific CD8 cells of acute patients.
Taken together, these data indicate that even though the
envelope-specific CD8 cells, which persist in chronically
infected patients, can be converted to a tet/pos phenotype,
they seem to maintain a different functional identity. To
further characterize the maturation state of these ‘converted’
cells we compared their phenotypic markers (Table II) with
those expressed by conventional tet/pos cells, which had
been expanded in parallel. Despite the same numbers of
rounds of in vitro restimulation, converted tet/pos CD8
Figure 4. Effect of antigenic stimulation on tetramer stain-
ing by env-183 specific CD8 cells. (A). PBMCs were stimu-
lated directly in vitro with peptide (1  M) and at 10–12 d in-
tervals expanded once (1 ) and twice (2 ) in vitro with
irradiated APC (EBV-B cells) pulsed with peptide (1  M).
Dot plots show Te183–91 staining directly ex vivo and after
20 d (1 ) and 30 d (2 ) of in vitro expansion. Numbers in
the top right dot plots indicate the percentage of total CD8
cells tet/pos. Numbers in boxes indicated the percentage of
total CD8 that produce IFN-  after peptide-specific stimula-
tion. Binding of Tc18–27 was always negative. (B) Tetramer-
binding assay in different populations of HBV-specific CD8
cells. Tet/pos converted cells specific for envelope 183–91 and
conventional tet/pos CD8 cells specific for core 18–27 (patients 1 and 5) and envelope 183–91 of patient 1 were incubated with graded concentration of
tetramers for 20 min at the indicated temperatures before adding anti-CD8. Cells were washed, fixed, and analyzed immediately by flow cytometry. Data
are shown as mean fluorescence intensity of double positive tet/CD8 population. (C) Tetramer dissociation assay. Tet/pos envelope 183 specific CD8
cells of chronic (converted tet/pos cells) and immune patients (tet/pos) were stained with saturating concentrations of Te183 (1  g/ml) at 37 C for 20
min before addition of anti-CD8 antibody. Cells were then washed (three times), kept at 4 C, and analyzed by FACS® at the indicated time points. Re-
sults are expressed as a percentage of tet/pos CD8  present at time 0.1095 Reignat et al.
cells maintain a less terminally differentiated phenotype
(CD38lo, CD56lo, and CD28h) than classical tet/pos CD8
cells (CD38h, CD56h, and CD28lo) (27). Of note, the dif-
ferences described in staining pattern and phenotype be-
tween “converted” and “classical” tet/pos cells argue against
the possibility of converted/tet pos cells being derived in
culture from a contaminating population of classical tet/pos
cells, but confirm their distinct functional identities.
Contribution of Tet/Neg CD8 Cells to HBV Control.
Having demonstrated the persistence of envelope-specific
CD8 cells in the circulation of chronically HBV-infected
patients we wanted to determine whether these cells exert
any immunological pressure on the virus or whether they
present defects in antiviral functions. The high level of
HBV replication present in these chronic patients (105–109
copies per milliliter) suggests that envelope-specific CD8
cells have a negligible effect on HBV replication, but spe-
cific mutations in envelope epitopes could allow virus to
escape CD8 control. Functionally active core 18–27 spe-
cific CD8 cells are demonstrable only in chronically in-
fected patients with virus mutations in the core epitope
(13, 20). Consistent with these previous findings, core 18–
27 specific CD8 were only efficiently expanded from pa-
tient 5, in whom the core sequence was mutated in posi-
tion 27, a mutation that reduces HLA-binding affinity (Fig.
1 and Table III). In contrast, expansion of envelope-spe-
cific CD8 cells was not attributable to mutations within the
corresponding envelope epitopes (Table III).
The lack of selective pressure exerted by the envelope-
specific cells prompted us to investigate whether these cells
are in a tolerant state or display alterations in antiviral func-
tions. Production of antiviral cytokines did not appear to
be impaired, since tet/neg CD8 cells produce IFN- , di-
rectly ex vivo and after in vitro culture (Fig. 1 B). Lytic
ability was tested in a conventional Cr51 release assay,
showing that envelope-specific tet/neg CD8 cells ex-
panded in vitro were able to lyse target cells pulsed with
the specific peptide (Fig. 5 B). Cells were also perforin pos-
itive by ICCS (data not shown). Ideally, cytolytic ability
should be tested directly ex vivo, since this function could
be altered by in vitro stimulation (7). However, the fre-
quency of HBV envelope-specific CD8 cells was too low
to allow detection of cytolytic ability ex vivo even in im-
mune subjects (data not shown).
A defect in clonal expansion could impair the ability of
virus-specific CD8 cells to expand and control viral replica-
tion (28), but the high frequency of envelope-specific CD8
cells in PBMCs of chronic patients after 10 d of culture sug-
gested that such an expansion defect was not operative. To
better analyze whether the envelope-specific CD8 cells of
chronic patients present a different activation threshold for
CD8 expansion, PBMCs of different immune and chronic
patients were stimulated directly after ex vivo purification
with varying doses of envelope 183–91 peptide. The quan-
tity of envelope-specific CD8 cells expanded by 10 d of in
vitro stimulation was tested with tetramer and ICCS (Fig. 5
A). Similar quantities of envelope peptide (1 uM–100 nM)
were necessary to expand envelope 183–91 specific cells
from PBMCs of chronic and immune patients. The only
difference between the cells expanded from chronic patients
and the ones present in immune patients is in the ability to
bind tetramers and not in the dose of peptide required for
CD8 expansion. These results show that tet/neg cells are
not in an anergic state and further support the finding that
these cells have comparable functional T cell avidity to tet/
pos cells. Interestingly, the expansion potential of envelope-
specific cells present in chronic patients is similar to that of
Table II. Phenotypic Analysis of CD8 Lines
Markers
CD8 line
chronic env 183
CD8 line immune
core 18-27
HLA-DR      
CD69        
CD56     
CD38     
CD62L      
CCR5   
CCR3   
CXCR3      
CD45 R0      
CD45 RA   
CD27   
CD28     
CD95      
  , high expression;  , intermediate;  / , low expression;  ,
absent.
Table III. Expansion of Epitope-specific CD8 Cells and 
Viral Sequence
Frequency of specific CD8 cells
Epitope 
sequence Patients Direct After expansion
Patient 4
Env 183–91 0.03% 9% WT
Core 18–27 0.02% 0% WT
Patient 5
Env 183–91 0.06% 2.8% WT
Core 18–27 0.04% 1.8% 127
Patient 6
Env 183–91 0.04% 2% WT
Core 18–27 0.02% 0.4% WT
Patient 7
Env 183–91 0.08% 9.4% WT
Core 18–27 0.02% 0% WT1096 Tetramer Negative CD8 Cells in Chronic Hepatitis B
resting CD8 cells present in immune patients. This was
tested by comparing the rate of division of core 18–27 spe-
cific CD8 cells of immune patients with the envelope 183–
91 specific CD8 cells of chronic patients. Circulating
PBMCs were labeled with the fluorescent dye CSFE and
stimulated with the envelope 183–91 (chronic) or core 18–
27 (immune) peptide. CSFE staining of CD8 cells was mea-
sured (Fig. 5 C) at the time of in vitro stimulation and after
10 or 12 d of in vitro culture. The results showed that the
efficiency of cell division reached after in vitro expansion
was identical for both populations (Fig. 5 C). Thus, tet/neg
cells of chronic patients have a potential capacity for in vitro
expansion similar to the immunodominant response seen in
patients who are able to control HBV infection.
Different Activation Requirements of Tet/Neg CD8 Cells.
Although we were unable to demonstrate any functional
deficits of tet/neg CD8 cells, this was difficult to reconcile
with the demonstrated absence of a selective pressure on
the virus, which suggests that envelope-specific CD8 cells
can ignore HBV in vivo. Ideally, the activation of enve-
lope-specific CD8 cells should be tested using infected
hepatocytes (29, 30) or liver endothelial cells (31) to mimic
physiological in vivo presentation. In the absence of such a
system, we compared the presentation of HLA–peptide
complexes by circulating APC and tetramers. MHC/pep-
tide oligomers have been used in other studies to dissect the
minimum requirements for T cell activation (32, 33). Fig. 6
A shows the experiments in which IFN-  production by
the different populations of HBV-specific CD8 cells found
in short term lines (10 d of in vitro expansion) was tested
after pulsing cells with a tetramer concentration that fully
stained specific CD8 cells (1  g/ml). In parallel, the same
Figure 5. Functional characterization of tet/neg CD8 cells. (A) Functional
TCR affinity of env183–91 CD8 cells of chronic and immune subjects. PBMCs
stimulated with different concentrations of peptides were tested after 10 d of
in vitro expansion for HLA-tetramer binding and peptide specific IFN- 
production. Bars represent the frequency of IFN- –producing CD8 cells af-
ter stimulation with different doses of env 183 peptide. Numbers in boxes
represent the percentage of tet/pos CD8 cells found in the same line. (B) Ly-
sis of peptide coated target cells (EBV-B cells) by tet/pos and tet/neg enve-
lope specific short-term CD8 lines. Lines examined with ICCS showed 4–5%
of peptide specific IFN- –producing CD8 cells and experiments were per-
formed with an E/T ratio of 10:1. (C) Proliferation of tet/neg envelope 183-
specific CD8 cells. PBMCs were labeled with CSFE before peptide specific
stimulation. Dye intensity was tested in total CD8 cells at day 1 and after 10 d
of in vitro expansion for peptide-specific IFN-y–producing CD8 cells. Histo-
grams show representative results obtained from patient 2 (immune/core 18–
27 specific CD8 cells) and patient 6 (chronic/env 183–91 specific CD8 cells).1097 Reignat et al.
CD8 cells were stimulated with APCs (B cells or macro-
phages) pulsed with peptides (1  M). Tet/pos CD8 cells
(core 18–27 and envelope 183–91 of immune (patient 1)
and core 18–27 of chronic (patient 5) patients could be
stimulated by tetramers alone to produce IFN- . In con-
trast, tetramers did not stimulate the production of IFN- 
by tet/neg CD8 cells (Fig. 6 A). Increasing the quantity of
tetramer or the time of stimulation (up to a maximum of
4 h) did not change the results (data not shown). Thus, the
lack of tetramer binding correlated with an inability to acti-
vate CD8 cells for IFN-  production.
More surprisingly, the envelope-specific CD8 cells (from
oligoclonal lines of chronic patients obtained after four
rounds of in vitro stimulation of antigen-specific selected
cells) were not activated by tetramers even after conversion
to a tet/pos phenotype (Fig. 6 B). Even when tet/pos ‘con-
verted’ CD8 cells acquired an intensity of fluorescent stain-
ing identical to classical tet/pos cells, these cells were still
not activated by tetramers, but only by peptide-loaded
APC (Fig. 6 B). Since activation of CD8 cells by tetramers
requires TCR clustering (32, 33), the inability of HLA-tet-
ramers to fully activate envelope-specific CD8 cells of
chronic patients suggests that tetramers alone are insuffi-
cient to cluster the TCRs in a way that permits full stimu-
lation. Alternatively, the TCRs may aggregate, but need
costimuli provided by target cells (34). These data show
that even after conversion to a tet/pos phenotype, the en-
velope-specific CD8 cells of chronic patients maintain dif-
ferent requirements for T cell activation in comparison
with “classical” tet/pos HBV-specific CD8 cells.
Selective Persistence of Tet/Neg CD8 Cells. During per-
sistent viral infection the TCR repertoire of virus-specific
CD8 cells is continuously selected (35). To determine
whether this feature might also apply to the altered tet-
ramer-binding CD8 cells persisting in chronic hepatitis B,
the V  profile and fine-specificity of the envelope-specific
CD8 cells generated in immune or chronic individuals was
tested. Envelope specific IFN- –producing CD8 cells
present in short-term lines were stained with a panel of 17
different V -specific antibodies. This V  antibody panel
covers approximately half of the available TCR repertoire,
but allows an assessment of oligo/polyclonality of the spe-
cific CD8 cells present in immune or chronically infected
subjects to be made.
Fig. 7 A shows that the V  usage of tet/neg envelope-
specific CD8 cells of chronic patients 4 and 7 was restricted
to V 17, whereas a more heterogeneous V  usage was dis-
played by envelope-specific CD8 cells of immune subjects.
Results from functional fingerprint experiments were con-
sistent with the broader T cell usage of immune subjects.
The production of IFN-  by envelope-specific CD8 cells
of immune (tet/pos) and chronic patients (tet/neg) was
stimulated with single alanine substituted env 183–91 ana-
logue peptides. Tet/pos envelope-specific CD8 cells of im-
mune patients displayed a degree of flexibility in the recog-
nition of the substituted peptides, whereas tet/neg cells of
chronic patients were activated only by the WT (nonmu-
tated) env 183–91 sequence (Fig. 7 B). Therefore, altered
tetramer binding is present only in a selected oligoclonal
envelope-specific CD8 population.
Figure 6. Analysis of CD8 activation with HLA-tetra-
mers. (A) Short-term CD8 lines (10 d in vitro expansion)
were stimulated with tetramers (1  g/ml) or with HLA-A2 
APC pulsed with 1  M of peptide. IFN- –producing
CD8 cells were examined with ICCS. Bars represent the
percentage of total CD8 cells producing IFN- . Represen-
tative experiments of chronic patient 5 and immune pa-
tient 1 are shown. A similar pattern was observed in
chronic patient 4 and 7 and in immune patient 2. (B) Con-
verted tet/pos cells are not activated by HLA tetramer.
Top dot plots show the phenotypic characterisation (tet-
ramer staining only) of a tet/pos core 18–27 specific CD8
oligoclonal line derived from an immune patient (patient
1) and of a converted tet/pos env 183–91 CD8 line of
chronic patient 6. Oligoclonal lines were produced after
selection and expansion (four rounds of in vitro stimula-
tion) of IFN- –producing cells. Bottom dot blots exam-
ined the same lines stained with tetramers and then stimu-
lated or not stimulated (tetramer only) with peptide pulsed
HLA-A2  APC. Lines were then tested with ICCS for
production of IFN- . Dot blots of gated CD8 cells are
shown. Note that the decreased staining intensity of Te
183–91 in the ICCS dot plots is explained by the faster de-
cay of tetramer binding present in converted tet/pos cells.
Numbers in the top corners represent the percentage of to-
tal CD8 cells producing IFN- .1098 Tetramer Negative CD8 Cells in Chronic Hepatitis B
Discussion
CD8 T cells in chronic viral infections (11) and tumors
(36) are prone to deletion or functional inactivation. A par-
ticular characteristic of chronic HBV infection is the pro-
duction of large quantities of subviral particles containing
only envelope antigens and associated host-derived lipid
(37, 38). These particles are present in a 103–106-fold ex-
cess over virions, reaching exceptional quantities of  3  
1013 particles per milliliter (1–300  g/ml; reference 39).
HBV subviral particles are noninfectious and the reason for
evolving this level of synthetic effort is not well under-
stood. A possible explanation is that this constitutes a way
of subverting the antiviral response. In this work we dem-
onstrate that a population of envelope-specific CD8 cells
persist in chronic hepatitis B, apparently escaping exhaus-
tion mediated by high concentrations of antigen. These vi-
rus-specific CD8 cells are not the classical tolerant cells,
since they can be stimulated in vitro to produce IFN- , as
well as being able to lyse and expand efficiently. However,
a population of specific CD8 cells with altered HLA/pep-
tide tetramer binding and ignoring HBV in vivo appear to
have been selected by envelope antigen.
Until now CD8 cells unable to efficiently bind MHC
class I tetramers have been observed in mouse models of vi-
ral infections (21, 23, 40) and in humans, in selected CTL
clones from a patient with melanoma (41). They have been
found in situations of high doses of viral antigen or with
partial/complete homology to self-peptide, reinforcing the
idea that tet/neg CD8 cells are a population of cells able to
persist in the presence of large amounts of cognate antigen.
It has been proposed that the mechanisms underlying
this altered tetramer binding may include TCR down-reg-
ulation and the selection of a low avidity T cell population
(11). The former is precluded by our data showing no
TCR downmodulation on tet/neg CD8 cells of chronic
patients. As regards the question of “low avidity T cells,”
this has been reported as an explanation for lack of tet-
ramer binding and increased tetramer dissociation rates
(40, 42). However, it is becoming increasingly clear that
HLA-tetramers cannot measure overall functional T cell
avidity (41, 43, 44), since this is often highly dependent on
other factors such as costimulatory molecules and signal
transduction pathways (45). Tetramer binding may reflect
the intrinsic TCR/MHC affinity (46), but even the accu-
racy of this is questionable due to the multivalent engage-
ment of tetramers (45) and their requirement for correct
TCR organization at the immunological synapse (24).
Thus, we cannot formerly exclude that tet/neg CD8 cells
have an intrinsic low TCR affinity, but data from three
different functional assays (IFN-  production, T cell ex-
pansion, and cytotoxicity) clearly show that they do not
represent low avidity T cells.
Our data are more in line with the explanation for al-
tered tetramer-binding proposed by Braciale et al. (21) as
representing a state of “incomplete T cell maturation.” In
their model of influenza-infected mice, they suggest that
tetramer-negativity may result from a defect in TCR orga-
nization (21), an hypothesis further supported by recent ex-
periments where T cells could be rendered “tet/neg” by
chemical disruption of lipid rafts and consequent loss of
normal TCR topology (24). The influenza-specific tet/neg
cells reverted to a tet/pos phenotype after repetitive in
vitro stimulation. In agreement with these data in mice, we
Figure 7. Narrow TCR usage of envelope-specific CD8 cells of chronic patients. (A) Analysis of V  usage of envelope specific CD8 cells of indicated
patients. PBMCs were stimulated with envelope peptide and after 10 d of in vitro expansion, cell lines were analyzed with ICCS for presence of peptide-
specific IFN- –producing CD8 cells. The percentage of IFN-  CD8 cells expressing each V  chain was calculated by analysis of at least 1,000 IFN- 
CD8  cells, indicated by bars. (B) Functional fingerprinting of envelope-specific CD8 cells of chronic and immune patients. PBMCs were stimulated
with 1  M of env 183–91 peptide (wt) and with analogue single alanine substituted peptides. Percentage of IFN-  CD8 cells specific for the wt peptide
was calculated after 10 d of in vitro expansion.1099 Reignat et al.
found that envelope-specific CD8 cells in the majority of
patients with chronic hepatitis B revert to a tet/pos pheno-
type after repetitive in vitro stimulation. This phenotypic
change can be explained by the demonstration that in vitro
T cell activation can modulate the plasma membrane choles-
terol content and redistribute the TCR to enhance MHC
dimer binding (25). Even though tetramer binding of these
envelope-specific CD8 cells can be promoted, the cells main-
tain peculiar features that still differentiate them from the
“classical” HBV-specific CD8 cells visualized by tetramers di-
rectly ex vivo. In this study we found that the reverted tet/
pos envelope-specific CD8 cells are insensitive to tempera-
ture-induced up-regulation of tetramer-binding. The fact that
staining is not augmented at physiological temperatures fur-
ther reinforces the possibility that processes such as redistribu-
tion of TCR, or tetramer internalization, are defective in these
cells. Future studies of membrane mobility, raft organization,
and TCR display will be needed to clarify these issues.
In addition to demonstrating the presence of virus-spe-
cific CD8 cells with altered tetramer binding, we also
found that the behavior of CD8 cells in patients with
chronic HBV infection differed according to their antigen
specificity. Here, and in previous work (13, 20), an effi-
cient core 18–27 specific CD8 response was only demon-
strated in the circulation of patients with chronic hepatitis
B when mutations in the core epitope were present. High
levels of replication (HBV-DNA  107 copies per millili-
ter) of nonmutated HBV are associated with an inability to
expand core 18–27 CD8 cells in the circulation. In con-
trast, env 183–91–specific CD8 cells are able to expand,
displaying the same proliferative potential, activation
threshold, and IFN-  production ability as memory CD8
cells present in immune individuals. This CD8 responsive-
ness is found in patients that show high levels of virus rep-
lication without mutations in the relevant epitopes, sug-
gesting that the functional activity of these cells in vitro is
not mirrored by the exertion of immunological pressure in
vivo. The tet/neg CD8 cells that persist in patients with
chronic HBV infection are therefore not ‘anergic’ but
seem more similar to the ‘ignorant’ cells present in mice
which express high quantities of antigen localized to pe-
ripheral sites (47–50) or the liver (51–53). Of note, the tet/
neg CD8 cells present in influenza-transgenic mice display
similar behavior, in that they ignore the product of the
transgene in vivo, but are not anergic, since tolerance can
be broken by viral infection (40).
The demonstration that different mechanisms can oper-
ate in the same host to silence antiviral CD8 responses has
already been reported in LCMV infection (9). In this mu-
rine infection, Zajac et al. have suggested that the impor-
tant parameter influencing the fate of CD8 cells specific for
different antigens could be the degree of activation. Our
findings may be in line with this interpretation. Despite
presenting similar HLA-A2–binding affinity, core 18–27
specific CD8 cells are numerically dominant over envelope
specificities in acute and resolved HBV infection, suggest-
ing that the core 18–27 epitope may be more immuno-
genic than the envelope specificities. This could depend on
the different quantity of envelope or core peptides pre-
sented at the surface of the infected cells. A further expla-
nation for the peculiar features of envelope-specific CD8
cells may be the fact that core and envelope antigens are
present in the patient in different forms and concentrations
(12). Core is preferentially (but not exclusively) a cell-asso-
ciated antigen (54), whereas envelope is present in large
quantity in a soluble form, making it the ideal substrate for
presentation by liver endothelial cells. These cells are a
population of nonmyeloid APCs, which are present in the
liver, and are specialized in the presentation of exogenous
soluble antigen, and in the induction of antigen-specific
CD8 cell tolerance (31).
Envelope-specific tet/neg CD8 cells might therefore es-
cape deletion by high dose of antigen because they are kept
in a state of “partial tolerance” by liver endothelial cells.
This interpretation could explain why, in vivo, these CD8
cells appear to ignore the infecting virus. This state of toler-
ance is clearly only partial. Tet/neg envelope-specific CD8
cells can be activated in vitro and the TCR repertoire of
tet/neg envelope-specific CD8 cells is narrower in chronic
patients than in immune, suggesting that only an oligo-
clonal population of CD8 cells is able to persist. Interest-
ingly, we have been unable to detect envelope-specific
CD8 cells in three patients with minimal liver injury, high
levels of HBV DNA, and a concentration of HBsAg  80
 g/ml (unpublished data), further suggesting that there is a
concentration threshold of envelope antigen above which
envelope-specific CD8 cells are deleted.
Whatever the explanations for the persistence of envelope-
specific CD8 cells in patients with chronic hepatitis B, the
demonstration that these cells are not fully anergic may have
important therapeutic implications. Thus, their presence
might explain the efficacy of envelope-based therapeutic vac-
cination in patients (55, 56) and animals with chronic hep-
adnavirus infections (57, 58). In addition, the demonstra-
tion that tumor or virus-specific CD8 cells which ignore
high doses of antigen can acquire protective properties in
vivo (59), might support the idea that indifferent CD8 cells
may represent a population of cells that can be expanded for
therapeutic use. It will also be interesting to see whether
the persistence of tet/neg CD8 cells is a general phenome-
non, occurring in other human chronic infections and tu-
mors, or is mainly dependent on the HBV liver tropism.
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